Seeking Alpha

Bristol-Myers' clazakizumab looks to be comparable to Humira in RA

  • Bristol-Myers Squibb (BMY) says clazakizumab appears to be comparable to Humira (ABBV) in reducing the symptoms of RA when taken in combination with methotrexate.
  • Trial results show 78% of patients taking clazakizumab with methotrexate saw their symptoms reduced by 20% versus 76% of patients taking Humira and methotrexate.
  • "We’re very excited about the results here, and we’re mapping out the next phases of the development plan,” BMY's Pushkal Garg tells Bloomberg.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: